Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279).
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Nottingham University Hospitals NHS Trust, Beatson West of Scotland Cancer Centre, University of Birmingham, Velindre Cancer Centre, St James's University Hospital, Torbay and South Devon NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, The Christie NHS Foundation Trust, Royal Marsden NHS Foundation Trust, Institute of Cancer Research
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2590615916